乳腺癌内分泌治疗进展

Development of endocrine therapy of breast cancer

乳腺癌的内分泌治疗是肿瘤综合治疗的重要组成部分之一。30多年来，三苯氧胺（TAM）已成为乳腺癌内分泌治疗的标准药物。第3代芳香化酶抑制剂的研制和开发，使乳腺癌内分泌治疗进入了一个崭新的时期。随着几个大型国际多中心、随机、双盲临床试验结果的不断公布，TAM在乳腺癌内分泌治疗中的金标准地位受到挑战。

Endocrinotherapy is an important part of comprehensive treatment for breast cancer. In recent thirty years,Tamoxifen becomes the standard endotherapeutic drug for breast cancer. The appearance of the third generation aromatase inhibitors brings the endotherapy of breast cancer into a new era. As the publication of the results of several large, multi- center, randomized and double blind clinical trials, the gold standard station of tamoxifen is challenged.